Abstract-Endothelin-1 (ET-1) has been proposed to contribute to atherogenesis and plaque rupture in coronary heart disease through activation of mitogen-activated protein kinases (MAPKs) in smooth muscle cells (SMCs). Reactive oxygen species (ROS) have been shown to be important signal transduction molecules in SMCs. Thus, the present study aimed to assess the role of ROS in ET-1-mediated activation of c-Jun amino-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) 1/2. Rat SMCs were exposed to ET-1 over time at concentrations from 10 Ϫ6 to 10 Ϫ10 mol/L, and MAPK activity was quantified. Activation of JNK and ERK was observed with a maximum stimulation at 10 Ϫ7 mol/L ET-1. JNK and ERK were activated by ET-1 binding to a single receptor (ET-1A) but differed in their downstream mechanisms: only JNK activation was sensitive to the radical scavenger N-acetylcysteine and diphenylene iodonium, an inhibitor of NADPH oxidase, indicating a role for ROS. The downstream MAPK effector and proinflammatory transcription factor, the activator protein-1 complex, was maximally activated 2 hours after the addition of ET-1. It was mainly composed of the JNK substrate c-Jun, and activation was also dependent on ROS formation. We suggest that plaque activation by ET-1 can be mediated through ROS. It can be hypothesized that the clinical benefit of antioxidants in the treatment of atherogenesis may partially depend on neutralization of ET-1-mediated ROS production. Key Words: endothelin-1 Ⅲ atherosclerosis Ⅲ reactive oxygen species Ⅲ mitogen-activated protein kinase Ⅲ smooth muscle S everal lines of evidence suggest a role for endothelin-1 (ET-1) in the pathogenesis of atherosclerosis, including immunohistochemical studies demonstrating an increased accumulation of ET-1 in human atheroma. 1 Furthermore, a direct correlation could be shown between the amount of ET-1 present in human coronary artery lesions and unstable angina. 2 In animal experiments, endothelin antagonists had a protective effect against atherosclerosis. 3,4 A release of endothelin, in vitro, by smooth muscle cells (SMCs) themselves was also demonstrated. 5 The proatherogenic properties of endothelin are attributed to its vasoconstrictive action, 2,6,7 and more recently, ET-1 has been reported to activate SMCs. 8,9 As shown by numerous studies, activation of SMCs can be an important step in the inflammatory response of the vessel wall. 10 The inflammatory response of SMCs involves a number of proteins of the signal cascade, including the inducible transcription factors c-Jun and c-Fos. 11 These are expressed at very low levels in quiescent SMCs but can be induced by stimulating SMCs with different agents, such as angiotensin II 12 or platelet-derived growth factor. 13 When activated, c-Jun and c-Fos can dimerize to form activator protein-1 (AP-1), a transcription factor complex. 14 Expression and activation of AP-1 proteins is tightly controlled by mitogen-activated protein (MAP) kinases, such as the c-Jun amino-terminal kinase (JNK) and extracellul...